| Model Name | Description |
| HEL 92.1.7 | The HEL 92.1.7 xenograft model is derived from human erythroleukemia and is used to study erythroid leukemia progression and test anticancer therapies. |
| MV4-11 | The MV4-11 xenograft model is derived from human acute myeloid leukemia (AML) with FLT3-ITD mutation and is used to evaluate targeted therapies against AML. |
| CCRF-CEM | The CCRF-CEM xenograft model is derived from human acute lymphoblastic leukemia (ALL) and is used to study aggressive T-cell leukemia and test chemotherapeutic agents. |
| KG-1 | The KG-1 xenograft model is derived from human acute myeloid leukemia and is used to evaluate therapies targeting early myeloid leukemia and drug resistance. |
| Kasumi-1 | The Kasumi-1 xenograft model is derived from human AML with t(8;21) translocation and is used to study leukemia progression and test targeted treatments. |
| Nalm-6 | The Nalm-6 xenograft model is derived from human pre-B acute lymphoblastic leukemia and is used to study B-cell leukemia biology and evaluate new therapies. |
| THP-1 | The THP-1 xenograft model is derived from human monocytic leukemia and is used to investigate myeloid leukemia and test experimental drugs. |
| SET-2 | The SET-2 xenograft model is derived from human megakaryoblastic leukemia and is used to study aggressive leukemia and evaluate novel therapies. |
| PL-21 | The PL-21 xenograft model is derived from human acute myeloid leukemia and is used to assess therapeutic responses in myeloid malignancies. |
| RS4;11 | The RS4;11 xenograft model is derived from human B-cell acute lymphoblastic leukemia and is used to study leukemia progression and test targeted therapies. |
| MEG-01 | The MEG-01 xenograft model is derived from human megakaryoblastic leukemia and is used to investigate platelet-producing leukemia and evaluate treatments. |
| KU812 | The KU812 xenograft model is derived from human chronic myeloid leukemia and is used to study leukemia biology and assess targeted therapies. |
| MOLM-14 | The MOLM-14 xenograft model is derived from human acute myeloid leukemia with FLT3-ITD mutation and is used to test targeted therapies and drug resistance. |